Non-Pharmacologic Therapy for Neurocardiogenic Syncope
NCT00096902 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45
Last updated 2017-07-02
Summary
This study will examine whether certain procedures that do not involve the use of medications can reduce symptoms of neurocardiogenic syncope (SIN-ku-pe), or a condition involving recurrent fainting. This condition is also known as vasovagal syncope or neurally mediated hypotension. Neurocardiogenic syncope is a disorder of the autonomic nervous system, which controls automatic body functions such as blood pressure, heart rate, and sweating. That system can be affected by medications, conditions of the mind or body, and by a person's surroundings. Researchers in this study wish to learn whether hypnosis, hand exercises, education, or diary keeping can affect the autonomic nervous system and improve symptoms of neurocardiogenic syncope.
Patients age 18 or older who have neurocardiogenic syncope may be eligible for this study. Those who have a medical illness making it unsafe to participate, who cannot discontinue certain medications, or who are pregnant are not eligible. Patients will undergo a medical history and physical examination, complete a questionnaire, and experience Valsalva and tilt table tests. These tests will take about 5 hours during 1 to 2 days.
The Valsalva test evaluates some of the reflexes of autonomic nervous system. Patients will lie flat on a padded table and have sensors placed on the body, to measure blood pressure, breathing rate, and other functions. They will blow into a sterile tube for 12 seconds while the body's responses are measured. The procedure may need to be repeated several times. During the test, an intravenous tube, guided by a needle, will be placed in the patient's arm. The tube will be used to collect samples of blood (less than 7 tablespoons) to measure chemicals such as adrenaline. For the tilt table test, a patient will lie on a padded, motorized table and have sensors placed on the body. Velcro straps will be placed around the patient's body to help hold him/her on the table. Then the table will tilt the patient from a flat position to an upright one in about 10 seconds. The patient will stay upright for 45 minutes while symptoms are monitored, measurements are taken, and blood samples are collected through the intravenous tube. Then the table will be returned to the flat position. If the patient faints or is about to faint, or if he or she has an unsafe heart rhythm before the 45 minutes is over, the test will be stopped and the table will be returned to the flat position. Symptoms will be treated as needed.
Patients who qualify for further study will then become familiar with hypnosis and be evaluated for their natural ability for experiencing it. A professionally trained doctor will guide patients into a hypnotic state, and patients will be asked to respond to various suggestions. They will be videotaped, an activity that will require a separate consent form. Following these procedures, patients will be assigned to one of the four groups in this study. Those in the hypnosis group will have weekly sessions for 6 weeks, with each session lasting about 1-1/2 hours. The education group will meet a study investigator for learning about syncope and the autonomic nervous system, with each session lasting about 1-1/2 hours once a week for 6 weeks. The hand exercise group will be taught certain hand exercises to perform, at home and as instructed, for 6 weeks. The diary group will receive instructions on keeping a diary pertaining to their condition, at home, for 6 weeks. After 6 weeks, patients will return for an evaluation to include completion of questionnaires and another tilt table test and blood collection by intravenous tube. This entire study will take about 8 weeks. There may be direct benefits from participating in this study. The experimental procedures may help patients' neurocardiogenic syncope.
After completing this study, patients will be offered any or all of the experimental procedures tested in this study upon their request and at the discretion of the principal investigator. For example, a patient who is assigned to the diary group may be offered hypnosis, education, and hand exercise instruction after completion of the study.
Conditions
- Syncope
Interventions
- PROCEDURE
-
Tilt table test
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-11-08
- Completion
- 2006-09-11
Countries
- United States
Study Locations
More Related Trials
-
The Effectiveness of Metoprolol in the Prevention of Syncope Recurrence in Children and Adolescents
NCT00475462 ·Status: COMPLETED ·Phase: NA
-
Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance
NCT00060866 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Autonomic Disorders: A Training Protocol
NCT02154009 ·Status: TERMINATED
-
Study of Atomoxetine in the Prevention of Vasovagal Syncope
NCT05159687 ·Status: RECRUITING ·Phase: PHASE3
-
Randomized Study of Midodrine, an Alpha Adrenergic Agonist, in Patients With Neurally Mediated Syncope
NCT00004479 ·Status: COMPLETED ·Phase: NA
-
Intravenous Norepinephrine for Orthostatic Hypotension
NCT01285908 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension
NCT00004268 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension
NCT00555880 ·Status: COMPLETED ·Phase: PHASE4
-
Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist
NCT03070730 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV
NCT01456481 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
The Pathophysiology of Orthostatic Hypotension
NCT00748059 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
NCT04620382 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Autonomic Determinants of POTS - Pilot 2
NCT04140721 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
NCT01518946 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study
NCT02308124 ·Status: COMPLETED ·Phase: PHASE4
-
Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)
NCT01000350 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study in Subjects With Neurogenic Orthostatic Hypotension
NCT07089043 ·Status: RECRUITING ·Phase: PHASE2
-
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
NCT02429557 ·Status: COMPLETED ·Phase: PHASE1
-
Empiric Quinidine for Asymptomatic Brugada Syndrome
NCT00789165 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Relation Between Vasovagal Tendency and Smoking Among University Students
NCT02949804 ·Status: COMPLETED
-
Autonomic Determinants of POTS - Pilot1
NCT04050410 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Nebivolol in the Supine Hypertension of Autonomic Failure
NCT01044693 ·Status: COMPLETED ·Phase: NA
-
Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic
NCT02726711 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
NCT02897063 ·Status: RECRUITING ·Phase: PHASE1
-
Sympathetic and Vascular Function in Takotsubo Syndrome
NCT05768542 ·Status: COMPLETED ·Phase: PHASE1/PHASE2